On Wednesday 26th October 2016 – Elucigene Diagnostics, developer and distributor of leading prenatal and human genetics diagnostics, and LifeCodexx AG, pioneer in cell-free fetal DNA testing in Europe, announced that they have partnered. Through this cooperation, UK and Irish patients will have access to LifeCodexx’ proprietary PrenaTest® NIPT technology.
PrenaTest® was Europe’s first non-invasive prenatal test (NIPT), significantly enhancing prenatal trisomy screening sensitivity, whilst drastically reducing invasive procedure linked pregnancy loss occurrence. The test is performed within Germany in strict conformity with the highest quality standards as per the European Directive on In-vitro Diagnostic Medical Devices. Currently, every 30 minutes a pregnant woman opts for PrenaTest® being a leading NIPT across Europe and the Middle East.
Dr. Mark Street-Docherty, Commercial Manager of Elucigene Diagnostics says “We are delighted to be able to offer pregnant women across the UK access to leading NIPT technology, ensuring safe and accurate screening for the most common chromosomal trisomies. This service complements our continued support for prenatal testing accuracy, alongside our leading QST*R diagnostic prenatal range”.
“We are very pleased to add Elucigene Diagnostics to our group of partners with their long standing expertise in the field of prenatal diagnostic in the U.K but also elsewhere,” added Dr. Michael Lutz, CEO of LifeCodexx. “With this new partnership, our high quality PrenaTest® is now available in more than 40 countries throughout Europe and the Middle East.”
PrenaTest® will be offered through the partnership with immediate effect, and interested patients and clinics should contact email@example.com for more detailed information.
About LifeCodexx AG
Headquartered in Konstanz (Germany), LifeCodexx AG has been developing innovative and clinically validated non-invasive diagnostic tests based on the newest molecular analytical methods since 2010. With the PrenaTest®, Europe’s first non-invasive prenatal test (NIPT) for the determination of the most common chromosomal disorders in unborn children, launched in 2012, LifeCodexx AG has been changing prenatal diagnostics considerably. The test is currently performed within Germany and Switzerland in strict conformity with the highest quality standards as per the European Directive on In-vitro Diagnostic Medical Devices.